This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
LGND or GMAB: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
LGND vs. GMAB: Which Stock Is the Better Value Option?
Is Elevance Health, Inc. (ELV) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Elevance Health (ELV) and Genmab AS Sponsored ADR (GMAB) have performed compared to their sector so far this year.
Genmab AS Sponsored ADR (GMAB) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Genmab AS Sponsored ADR (GMAB) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Ensign Group (ENSG) Facility Buyout to Boost Colorado Foothold
by Zacks Equity Research
Ensign Group (ENSG) acquires two skilled nursing facilities in Colorado that are likely to grow its healthcare portfolio and solidify its nationwide presence.
Oncolytics Biotech Inc. (ONCY) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Oncolytics Biotech Inc. (ONCY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks.com featured highlights include Tap Genmab, KnowBe4, UserTesting, Enphase Energy and Gartner
by Zacks Equity Research
Tap Genmab, KnowBe4, UserTesting, Enphase Energy and Gartner are part of the Zacks Screen of the Week article.
5 Top Stocks to Tap Earnings Beat Potential
by Sanghamitra Saha
Buy shares of Genmab (GMAB), KnowBe4 (KNBE), UserTesting (USER), Enphase Energy (ENPH) and Gartner (IT).
Here's What's Driving AbbVie's (ABBV) Outperformance This Year
by Zacks Equity Research
AbbVie (ABBV) boasts several new drugs with the potential to drive revenues once Humira loses U.S. exclusivity in 2023. Its early and mid-stage pipeline has several candidates with blockbuster potential.
Is Elevance Health, Inc. (ELV) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Elevance Health (ELV) and Genmab AS Sponsored ADR (GMAB) have performed compared to their sector so far this year.
AbbVie (ABBV) BLA for Epcoritamab Gets FDA Priority Tag
by Zacks Equity Research
The FDA grants priority review status to AbbVie's (ABBV) BLA for epcoritamab for the relapsed/refractory large B-cell lymphoma (LBCL), a form of NHL.
Humana's (HUM) Arm to Aid Senior Care, 2023 Expansion on Track
by Zacks Equity Research
Humana's (HUM) CenterWell brand plans to open centers in untapped markets as well as dig deeper into the existing regions offering enhanced primary care services to the nation's senior citizens.
Can Genmab AS Sponsored ADR (GMAB) Run Higher on Rising Earnings Estimates?
by Zacks Equity Research
Genmab AS Sponsored ADR (GMAB) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Genmab AS Sponsored ADR (GMAB) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Genmab AS Sponsored ADR (GMAB) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
PBYI vs. GMAB: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PBYI vs. GMAB: Which Stock Is the Better Value Option?
Is Genmab (GMAB) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Genmab AS Sponsored ADR (GMAB) and Nuvalent, Inc. (NUVL) have performed compared to their sector so far this year.
Is a Surprise Coming for Genmab (GMAB) This Earnings Season?
by Zacks Equity Research
Genmab (GMAB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
4 Biotech Stocks Set to Outpace Q3 Earnings Estimates
by Sundeep Ganoria
Let us take a look at some biotech stocks, ARGX, BMRN, LLY and GMAB, which are poised to beat on third-quarter earnings.
Centene (CNC) to Post Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Centene's (CNC) third-quarter results are likely to reflect higher premiums and contract wins enjoyed by its Medicaid business, partly offset by escalating operating expenses.
INCY vs. GMAB: Which Stock Is the Better Value Option?
by Zacks Equity Research
INCY vs. GMAB: Which Stock Is the Better Value Option?
Will UnitedHealth Group (UNH) Beat Q3 Earnings Estimates?
by Zacks Equity Research
UnitedHealth Group's (UNH) third-quarter results are likely to benefit from higher premiums and membership growth in its UnitedHealthcare unit, partly offset by elevated technology investment costs.
Should You Buy Genmab (GMAB) Ahead of Earnings?
by Zacks Equity Research
Genmab (GMAB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Genmab (GMAB), AbbVie's Epcoritamab Successful in LBCL Study
by Zacks Equity Research
Genmab (GMAB) and AbbVie are co-developing epcoritamab as a potential treatment for hematologic malignancies including NHL and LBCL. A phase I/II study evaluating it in LBCL achieves a response rate of 63%.
Seagen (SGEN) Inks ADC Deal With Sanofi for Cancer Targets
by Zacks Equity Research
Seagen (SGEN) inks a collaboration agreement with Sanofi to develop and commercialize antibody-drug conjugates for three cancer targets.
Genmab (GMAB), AbbVie Lymphoma Candidate Gets Orphan Drug Tag
by Zacks Equity Research
Genmab (GMAB) and AbbVie are co-developing epcoritamab as a potential treatment for non-Hodgkin's lymphoma, follicular lymphoma. The FDA grants orphan drug status for the candidate as a treatment for FL.
Seagen's (SGEN) Cancer Portfolio Strong, Stiff Rivalry a Worry
by Zacks Equity Research
Seagen (SGEN) focuses on improving sales of its marketed drugs that are approved for different types of cancer indications. Stiff competition in the target market remains a woe.